-

Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Report highlights progress toward environmental, social and governance objectives

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company’s commitment to society and stakeholders providing detailed insight into the company’s CSR progress and environmental, social and governance (ESG) efforts.

“Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Reducing our impact on the environment, fostering an inclusive culture and being active members of our communities gives our more than 100,000 colleagues the opportunity to make a difference every day.”

Highlights from the company’s annual CSR report include:

Environment

  • Achieved 12% reduction in absolute Scope 1 and 2 emissions compared to 2018, putting the company ahead of schedule towards its 2030 target to reduce Scope 1 and 2 greenhouse gas emissions by 30%, even as it expanded global capacity in 2020 and 2021.
  • Committed to net-zero emissions across its value chain by 2050, aligning the company’s climate strategy and goals with the Paris Agreement, and expanding on its existing 2030 target.

Operations

  • Increased direct and indirect spending with small and traditionally underrepresented businesses from $1.3 billion to $2.0 billion. This is part of a Supplier Diversity Program designed to proactively promote more inclusive procurement practices that reflect the company’s customer base, employees and communities.
  • Continued mobilization of company resources to accelerate development, manufacturing and distribution of products critical to the global pandemic response, becoming one of the largest testing suppliers to global relief organizations for use in more than 100 low- and middle-income countries.

Communities

  • Reached more than 100,000 students and 6,600 educators through science, technology, engineering and math (STEM) programming across 21 countries.
  • Volunteered more than 105,000 hours worldwide through local Community Action Councils.

Colleagues

  • Advanced its diversity and inclusion strategy including demonstrated progress in improving representation within company leadership positions.

In reporting our CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks including the Global Reporting Initiative (GRI) Sustainability Reporting Standards, United Nations Sustainable Development Goals (SDGs), the Value Reporting Foundation’s SASB Standards and the Task Force on Climate-related Financial Disclosures (TCFD). The company makes additional topic-specific ESG data available through CDP, EcoVadis, and the voluntary disclosure of its annual EEO-1 information.

Learn more at www.thermofisher.com/csr

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Ron O’Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com

Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com

More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom